Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study

BACKGROUND: Limited real-world data exist on the effectiveness and safety of abiraterone acetate plus prednisone (abiraterone hereafter) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) naive to chemotherapy. Most of the few available studies had a retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Procopio, G., Chiuri, V.E., Giordano, M., Alitto, A.R., Maisano, R., Bordonaro, R., Cinieri, S., Rossetti, S., De Placido, S., Airoldi, M., Galli, L., Gasparro, D., Ludovico, G.M., Guglielmini, P.F., Carella, C., Nova, P., Aglietta, M., Schips, L., Beccaglia, P., Sciarra, A., Livi, L., Santini, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058899/
https://www.ncbi.nlm.nih.gov/pubmed/35405438
http://dx.doi.org/10.1016/j.esmoop.2022.100431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058899/
https://www.ncbi.nlm.nih.gov/pubmed/35405438
http://dx.doi.org/10.1016/j.esmoop.2022.100431

Ejemplares similares